On Monday, Shares of ARM Holdings plc (ADR) (NASDAQ:ARMH), lost -0.58% to $44.22.
A new device to assist tackle sleep apnea has claimed first prize in the ARM Smart Product Design Competition. The Apnea Observer was designed by developer Clemente di Caprio from Rome, Italy, who has been awarded $5,000 to assist advance his prototype. Sleep apnea affects up to a quarter of the general population according to the British Journal of Anaesthesia, with 90 percent of sufferers remaining undiagnosed. If left untreated, this chronic sleep condition can lead to serious health problems counting diabetes, high blood pressure, heart disease, stroke and weight gain.
The competition was launched in February 2015 to raise awareness of how easily products can be designed with ARM CMSIS software components and middleware. It attracted more than 700 entries, with 350 moving to the development phase where entrants could choose to work with ARM Cortex®-M processor-based development boards from Freescale, Infineon, NXP or STMicroelectronics. Fourteen entries were selected as finalists, with the three prize-winners chosen by a panel of judges counting Jens Nickel (Elektor), Reinhard Keil (ARM) and Christopher Seidl (ARM).
ARM Holdings plc, together with its auxiliaries, designs microprocessors, physical intellectual property (IP), and related technology and software. The company also sells development tools that enhance the performance of embedded applications. Its products comprise microprocessor cores that comprise of specific functions, such as video, graphics, and display technology IP; and physical IP components for the design and manufacture of integrated circuits, which comprise embedded memory, standard cell, and input/output components.
Shares of Century Aluminum Co (NASDAQ:CENX), declined -3.02% to $5.46, during its last trading session.
Century Aluminum of Kentucky, declared the orderly curtailment of one potline at its Hawesville, Kentucky aluminum smelter, effective right away. Following the curtailment, Hawesville’s primary aluminum production will be about 60% of capacity. The plant was operating at about 80% capacity preceding to the curtailment. Century Aluminum of Kentucky formerly issued a notice of its intent to curtail its plant operations in their entirety startning on October 24, 2015, unless the current pricing environment substantially changes, and such notice remains in effect.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1995 and is headquartered in Chicago, Illinois.
At the end of Monday’s trade, Shares of PDL BioPharma Inc (NASDAQ:PDLI), lost -2.27% to $5.16.
PDL BioPharma, declared that it has attained a portion of the royalties on predictable sales of AcelRx Pharmaceuticals Inc.’s (ACRX) Zalviso™ (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its commercial partner, Grunenthal. Under the terms of the agreement, PDL has offered AcelRx with gross proceeds of $65 million, and in exchange, PDL will receive 75 percent of the royalties AcelRx receives from Grunenthal in addition to 80 percent of the first four commercial milestones subject to a capped amount.
Zalviso is a combination drug and device product which, using a patient controlled dispenser, delivers a sub-lingual formulation of sufentanil, an opioid with a high therapeutic index. It is being evaluated for the treatment of moderate to severe post-operative pain in the hospital setting and could be used in lieu of intravenous patient-controlled analgesia (IV PCA). Zalviso has been presented for product approval in the European Union and has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Pending approval, Grunenthal anticipates to launch Zalviso startning in the first half of 2016, and PDL anticipates to start receiving royalties shortly thereafter.
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
Finally, Apple Hospitality REIT Inc (NYSE:APLE), ended its last trade with 0.21% gain, and closed at $18.95.
Apple Hospitality REIT, declared that its Board of Directors declared a regular monthly cash distribution of $0.10 per common share for the month of October 2015. The distribution is payable on October 15, 2015, to shareholders of record as of September 30, 2015.
Based on the Company’s common stock closing price of $19.77 on September 17, 2015, the annualized distribution of $1.20 per common share represents an annual 6.1% yield.
Apple Hospitality REIT, Inc. is a publicly owned real estate investment trust. It invests in the real estate markets of United States. The firm invests primarily in the lodging industry. It is focused on the acquisition and ownership of income-producing real estate.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
